


Technology Advisory Committee A Interests Register

Topic: Albemaciclib in combination with endocrine therapy for adjuvant treatment of hormone receptor positive HER2-negative node-positive early breast cancer [ID3857]

Publication Date: 20.07.2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Holly Heath	Patient expert	Indirect financial	In the last 12 months Breast Cancer Now has received funding from the manufacturer Eli Lilly and possible comparator companies Novartis and Pfizer either towards their living with secondary breast cancer support service or service pledge work with hospitals.	N/A	15.10.2021	N/A	It was agreed that her declaration would not prevent Holly from providing expert advice to the committee.
Dr Andreas Makris	Clinical expert	Direct financial	Dr Makris has received advisory board and speaker fees from Eli Lilly.	N/A	28.09.2021	N/A	It was agreed that his declaration would not prevent Dr Makris from providing expert advice to the committee.
Dr Olga Oikonomidou	Clinical expert	Direct non- financial	Dr Oikonomidou is the local PI on the MonarchE and the MONARCHER study.	N/A	21.09.2021	N/A	It was agreed that her declaration would not prevent Dr Oikonomidou from providing expert advice to the committee



GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest arose and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.